Cargando…
Ex vivo generation of platelet products from human iPS cells
Platelet products are used in treatments for thrombocytopenia caused by hematopoietic diseases, chemotherapy, massive hemorrhages, extracorporeal circulation, and others. Their manufacturing depends on volunteers who donate blood. However, it is becoming increasingly necessary to reinforce this bloo...
Autores principales: | Nakamura, Sou, Sugimoto, Naoshi, Eto, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708911/ https://www.ncbi.nlm.nih.gov/pubmed/33292717 http://dx.doi.org/10.1186/s41232-020-00139-2 |
Ejemplares similares
-
Ex Vivo Production of Platelets From iPSCs: The iPLAT1 Study and Beyond
por: Sugimoto, Naoshi, et al.
Publicado: (2023) -
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets
por: Chen, Si Jing, et al.
Publicado: (2022) -
Generation and manipulation of human iPSC-derived platelets
por: Sugimoto, Naoshi, et al.
Publicado: (2021) -
Development of platelet replacement therapy using human induced pluripotent stem cells
por: Nakamura, Sou, et al.
Publicado: (2021) -
Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell‐Derived Platelets
por: Hirata, Shinji, et al.
Publicado: (2016)